{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:28:55Z","timestamp":1789014535355,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.eururo.2014.02.013","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T12:45:45Z","timestamp":1392900345000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort"],"prefix":"10.1016","volume":"67","author":[{"given":"Ethan","family":"Basch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Autio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia V.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Scheffold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Harzstark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Schimmoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.02.013_bib0005","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic monogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.02.013_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JOP.2013.000876","article-title":"Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure","volume":"9","author":"Autio","year":"2013","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.eururo.2014.02.013_bib0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12094-011-0719-5","article-title":"MET and VEGF: synergistic targets in castration-resistant prostate cancer","volume":"13","author":"Aftab","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0020","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","article-title":"High expression of the Met receptor in prostate cancer metastasis to bone","volume":"60","author":"Knudsen","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.02.013_bib0025","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.eururo.2014.02.013_bib0030","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0040","doi-asserted-by":"crossref","unstructured":"De Bono JS, Smith MR, Rathkopf D, et al. Cabozantinib (XL184) at 40mg in patients with metastatic castration resistant prostate cancer (mCRPC): results of a phase 2 non-randomized expansion cohort (NRE). Presented at: European Society for Medical Oncology Congress; September 28 to October 2, 2012; Vienna, Austria.","DOI":"10.1016\/S0923-7534(20)33492-X"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.02.013_bib0045","article-title":"Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): results from a phase II nonrandomized expansion cohort (NRE) [abstract 4513]","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0050","unstructured":"US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM193282.pdf. Accessed October 28, 2013."},{"key":"10.1016\/j.eururo.2014.02.013_bib0055","unstructured":"US Food and Drug Administration. Guidance for industry. Qualification process for drug development tools. 2010. US Food and Drug Administration Web site. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM230597.pdf. Accessed October 28, 2013."},{"key":"10.1016\/j.eururo.2014.02.013_bib0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jval.2012.03.1385","article-title":"Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels","volume":"15","author":"Basch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2014.02.013_bib0180","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.28470","article-title":"Pain palliation measurement in cancer clinical trials: the FDA perspective","volume":"120","author":"Basch","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.02.013_bib0070","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0075","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.02.013_bib0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.02.013_bib0085","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2014.02.013_bib0090","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0095","doi-asserted-by":"crossref","first-page":"A431","DOI":"10.1016\/j.jval.2012.08.2159","article-title":"PCN119 patient-reported outcomes (PROs) in antineoplastic product approvals in Europe and in the USA","volume":"15","author":"Patrick","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2014.02.013_bib0100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2014.02.013_bib0105","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.eururo.2014.02.013_bib0185","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2013.54.5954","article-title":"Cabozantinib in chemotherapy-pretreated metastatic castrationresistant prostate cancer: results of a phase II nonrandomized expansion study","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2014.02.013_bib0120","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0125","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.eururo.2014.02.013_bib0130","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer: the M. D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.02.013_bib0135","unstructured":"Swarm R, Pickar Abernethy A, Anghelescu DL, et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: adult cancer pain (version 2.2011). National Comprehensive Cancer Network Web site. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1016\/j.eururo.2014.02.013_bib0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(94)00178-H","article-title":"When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function","volume":"61","author":"Serlin","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2014.02.013_bib0145","doi-asserted-by":"crossref","first-page":"e78881","DOI":"10.1371\/journal.pone.0078881","article-title":"Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling","volume":"8","author":"Nguyen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2014.02.013_bib0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/1078-0432.CCR-13-0839","article-title":"Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions","volume":"20","author":"Dai","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2014.02.013_bib0155","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2011.39.2381","article-title":"Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer","volume":"30","author":"Fisch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.02.013_bib0160","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.02.013_bib0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1526-4637.2009.00774.x","article-title":"The Brief Pain Inventory and its \u201cpain at its worst in the last 24 hours\u201d item: clinical trial endpoint considerations","volume":"11","author":"Atkinson","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.eururo.2014.02.013_bib0170","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814001328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814001328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:10Z","timestamp":1759583050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814001328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0302283814001328"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.02.013","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}